KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Common Equity (2020 - 2026)

AbCellera Biologics filings provide 7 years of Common Equity readings, the most recent being $938.1 million for Q1 2026.

  • Quarterly Common Equity fell 8.3% to $938.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $938.1 million through Mar 2026, down 8.3% year-over-year, with the annual reading at $966.9 million for FY2025, 8.44% down from the prior year.
  • Common Equity hit $938.1 million in Q1 2026 for AbCellera Biologics, down from $966.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.3 billion in Q3 2022 and bottomed at $938.1 million in Q1 2026.
  • Average Common Equity over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
  • The largest annual shift saw Common Equity soared 31.13% in 2022 before it fell 10.58% in 2025.
  • AbCellera Biologics' Common Equity stood at $1.2 billion in 2022, then decreased by 6.56% to $1.2 billion in 2023, then dropped by 8.35% to $1.1 billion in 2024, then fell by 8.44% to $966.9 million in 2025, then fell by 2.98% to $938.1 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Common Equity are $938.1 million (Q1 2026), $966.9 million (Q4 2025), and $964.0 million (Q3 2025).